|
Price: $164.9400
$7.69 
4.890%
|
| Day's High:
| $165.03
| Week Perf:
| 3.44 %
|
| Day's Low: |
$ 154.75 |
30 Day Perf: |
25.47 % |
| Volume (M): |
574 |
52 Wk High: |
$ 200.98 |
| Volume (M$): |
$ 94,643 |
52 Wk Avg: |
$164.14 |
| Open: |
$156.01 |
52 Wk Low: |
$110.45 |
|
|
| Market Capitalization (Millions $) |
9,367 |
| Shares
Outstanding (Millions) |
57 |
| Employees |
1,170 |
| Revenues (TTM) (Millions $) |
670 |
| Net Income (TTM) (Millions $) |
116 |
| Cash Flow (TTM) (Millions $) |
107 |
| Capital Exp. (TTM) (Millions $) |
28 |
Repligen Corp
Repligen Corp is a biotechnology company that specializes in the manufacture and supply of bioprocessing products and technologies.
The company's product portfolio includes Protein A and G ligands, affinity chromatography resins, growth factor supplements for cell culture, and filtration products for virus and gene therapy production.
Repligen Corp was founded in 1981 and is headquartered in Waltham, Massachusetts.
The company's manufacturing facilities are located in Waltham, Massachusetts and Lund, Sweden.
Repligen Corp serves customers in the biopharmaceutical and biotechnology industries worldwide.
The company has a strong focus on the development of novel and innovative technologies that enhance productivity and efficiency in bioprocessing.
This has led to the creation of several proprietary technologies such as the OPUS pre-packed chromatography columns and the ATF (Alternating Tangential Flow) system for high-density cell culture perfusion.
One of Repligen Corp's key strengths is its ability to meet the stringent quality standards of the bioprocessing industry.
The company is ISO 9001:2015 certified and adheres to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) guidelines.
Overall, Repligen Corp is an established player in the bioprocessing industry with a strong track record of innovation and quality.
The company's focus on the development of new products and technologies that increase the efficiency and productivity of bioprocessing is expected to position it for continued growth and success in the future.
Company Address: 41 Seyon Street, Bldg. 1, Suite 100 Waltham 2453 MA
Company Phone Number: 250-0111 Stock Exchange / Ticker: NASDAQ RGEN
| RGEN is expected to report next financial results on February 21, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Calidi Biotherapeutics Inc
The stockholders of were taken by surprise as the company reported unexpected modifications in revenue figures during the July to September 30, 2023 reporting season. While the markets display less concern about the current organizational and operational excellence of the Biotechnology and Pharmaceuticals company (CLDIsn), the shareholders are eagerly awaiting the development of new revenue sources to strengthen the company's financial position.
During the mentioned reporting period, CLDIs faced an operating deficit of $-7.221 million, indicating considerable financial challenges. This significant deficit has raised concerns among stakeholders, as the company is still in the early stages of its development. Investors are now emphasizing the urgency of generating new revenue streams, underscoring the importance of increasing capital to sustain business operations.
|
|
Xtant Medical Holdings Inc
Xtant Medical Holdings Inc Turns Profitable, Signaling Strong Growth Potential
BELGRADE, Mont., Oct. 12, 2023 - Xtant Medical Holdings Inc (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal disorders, has announced impressive financial results for the most recent fiscal period. The company's turnaround to a surplus has caught the attention of investors, with income per share standing at $0.07 compared to a loss of $0.03 per share a year ago. Furthermore, Xtant Medical Holdings Inc achieved a positive income per share of $0.02 in comparison to a loss of $0.02 per share in the preceding reporting period.
One of the key factors contributing to their success is the substantial revenue growth of 68.262%, reaching $24.33 million from $14.46 million in the same reporting period last year. Sequentially, the company also witnessed a notable improvement of 25.053% from $19.46 million. The surge in revenue reflects Xtant Medical Holdings Inc's strong market presence and the increasing demand for its products.
|
|
Instil Bio Inc
Date: November 14, 2023
Following the big players in the Biotechnology and Pharmaceuticals industry, some overlooked entities are reporting their financial numbers for the third quarter of 2023. Two such companies, TIL and Instil Bio Inc, have recently released their Q3 financial results, which reflect varying degrees of success and challenges within their respective operations.
TIL, a company focused on developing tumor infiltrating lymphocyte therapies for cancer treatment, reported an operating shortfall of $-66.716 million for Q3 2023. This decrease in performance is likely to raise concerns among investors who were eagerly hoping for improvements in TIL's business model during this period. TIL is expected to attract additional investments to support growth and strategy enhancements.
|
|
Semper Paratus Acquisition Corporation
The Biotechnology and Pharmaceuticals sector has been closely monitoring the third-quarter earnings of Semper Paratus Acquisition Corporation, one of the key players in the industry. Experts in the sector are currently analyzing the company's financial performance to gain insights into its future prospects.
According to the latest reports, Semper Paratus Acquisition Corporation recorded an operating deficit of $-0.605971 million during the July to September 2023 quarter. These figures are concerning, especially considering that the company had achieved an operating deficit of $0.198832 million during the same period in 2022. This indicates a deterioration in the company's overall financial health.
|
|
Ladrx Corporation
The stock market is an ever-evolving landscape, filled with opportunities for both investors and corporations alike. In the Biotechnology and Pharmaceuticals sector, some companies often go unnoticed, but they are now emerging with promising earnings. One such corporation is Ladrx Corporation, which recently reported a decrease in its operating shortfall for the third quarter of 2023.
In comparison to the third quarter of 2022, Ladrx Corporation's operating shortfall has significantly improved. Last year, the company experienced an operating shortfall of $-1.167527 million. However, this year, the shortfall has decreased to $-0.840313 million. These numbers serve as crucial signals for the state of Ladrx Corporation, indicating a positive trend in the company's financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
2.04 $ |
| Revenues (TTM) |
11.79 $
|
| Cash Flow (TTM) |
1.89 $ |
| Cash |
11.11 $
|
| Book Value |
35.02 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
2.04 $
|
| Revenues (TTM) |
11.79 $ |
| Cash Flow (TTM) |
1.89 $ |
| Cash |
11.11 $
|
| Book Value |
35.02 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
